We are live on ! Find out more
FO

FT Options Portfolio holdings

AUM $66.4M
1-Year Est. Return 18.48%
This Fund
S&P 500
This Quarter Est. Return
+2.11%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$66.4M
AUM Growth
+$8.29M
Cap. Flow
+$122M
Cap. Flow %
183.83%
Top 10 Hldgs %
32.21%
Holding
297
New
108
Increased
49
Reduced
51
Closed
72

Top Buys

1
INCY icon
Incyte
INCY
+$3.53M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$2.94M
3
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$2.18M
4
ARAV
Aravive, Inc. Common Stock
ARAV
+$1.54M
5
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$1.37M

Top Sells

1
GIS icon
General Mills
GIS
+$2.52M
2
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$2.31M
3
AMGN icon
Amgen
AMGN
+$2.08M
4
ABT icon
Abbott
ABT
+$1.72M
5
CLVS
Clovis Oncology, Inc.
CLVS
+$1.56M

Sector Composition

1 Healthcare 41.81%
2 Consumer Discretionary 7.1%
3 Consumer Staples 6.25%
4 Communication Services 0.99%
5 Materials 0.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HLF icon
126
PUT
Herbalife
HLF
$1.28B
$47K 0.07%
+30,000
New +$1.03M
JUNO
127
DELISTED
Juno Therapeutics, Inc.
JUNO
$45K 0.07%
+1,000
New +$34.1K
SAGE
128
CALL
DELISTED
Sage Therapeutics
SAGE
$44K 0.07%
+3,300
New +$259K
VZ icon
129
CALL
Verizon
VZ
$183B
$44K 0.07%
30,000
+12,500
+71% +$588K
JWN
130
CALL
DELISTED
Nordstrom
JWN
$43K 0.06%
+58,000
New +$2.69M
DVA icon
131
PUT
DaVita
DVA
$15B
$41K 0.06%
25,000
-8,500
-25% -$512K
FOLD
132
PUT
DELISTED
Amicus Therapeutics
FOLD
$41K 0.06%
+35,100
New +$464K
HSIC icon
133
PUT
Henry Schein
HSIC
$10.1B
$40K 0.06%
+30,345
New +$2.07M
COL
134
CALL
DELISTED
Rockwell Collins
COL
$40K 0.06%
+11,000
New +$1.34M
ONCE
135
CALL
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$37K 0.06%
+20,000
New +$1.52M
ILMN icon
136
PUT
Illumina
ILMN
$28.8B
$36K 0.05%
7,299
– –
RCKT icon
137
Rocket Pharmaceuticals
RCKT
$372M
$36K 0.05%
5,000
-32,500
-87% -$149K
GGP
138
DELISTED
GGP Inc.
GGP
$36K 0.05%
+1,757
New +$38.4K
TMUS icon
139
CALL
T-Mobile US
TMUS
$209B
$34K 0.05%
+20,100
New +$1.26M
GWPH
140
CALL
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$34K 0.05%
9,100
– –
TTPH
141
CALL
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$34K 0.05%
+3,750
New +$502K
DBVT
142
PUT
DBV Technologies
DBVT
$880M
$33K 0.05%
+2,450
New +$1.05M
GIS icon
143
PUT
General Mills
GIS
$20.7B
$33K 0.05%
5,000
-58,000
-92% -$3.18M
UTHR icon
144
CALL
United Therapeutics
UTHR
$22.5B
$33K 0.05%
+10,700
New +$1.37M
CL icon
145
CALL
Colgate-Palmolive
CL
$75.3B
$32K 0.05%
31,500
-33,300
-51% -$2.4M
BIG
146
CALL
DELISTED
Big Lots, Inc.
BIG
$32K 0.05%
+8,200
New +$404K
SIOX
147
CALL
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$32K 0.05%
22,350
+21,975
+5,860% +$3.71M
KHC icon
148
PUT
Kraft Heinz
KHC
$31.1B
$30K 0.05%
2,000
– –
MOS icon
149
CALL
The Mosaic Company
MOS
$7.16B
$30K 0.05%
+15,000
New +$325K
PRGO icon
150
CALL
Perrigo
PRGO
$1.54B
$29K 0.04%
+15,000
New +$1.17M
4 5
6
7 8

Similar funds

MC
Micawber Capital Seattle, Washington $62.9M AUM 20.32% 1-Year Est. Return
FIM
Friedberg Investment Management Houston, Texas $61.9M AUM 20.07% 1-Year Est. Return
TLIC
Thai Life Insurance Company Bangkok, Thailand $71M AUM 20.14% 1-Year Est. Return
MKCM
Mount Kellett Capital Management New York $61M AUM 12.22% 1-Year Est. Return
ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
MFM
Marianas Fund Management New York $58.1M AUM 10.84% 1-Year Est. Return
VE
Vega Energy New York $75.5M AUM 15.36% 1-Year Est. Return
GFWEV
G.F.W. Energy VIII Irving, Texas $76.3M AUM 11.41% 1-Year Est. Return

FT Options's Q3 2017 Portfolio in Review

As of Q3 2017, FT Options held 297 positions worth $66.4M, up 14% from $58.1M the previous quarter. Its ten largest holdings account for 32% of the portfolio.

FT Options deployed $122M of net new capital in Q3 2017, opening 108 new positions and adding to 49 existing holdings. Its largest new stake was Incyte: 27,887 shares worth $3.26M.

By sector, the portfolio is most concentrated in Healthcare at 42% of assets, up from 38% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.

On the sell side, the largest reduction was General Mills, an estimated $2.52M trimmed.

  • FT Options's largest Q3 2017 buy was Incyte: 27,887 shares worth $3.26M.
  • FT Options added most to Sio Gene Therapies Inc. Common Stock in Q3 2017, an estimated $1.37M increase.
  • FT Options's biggest Q3 2017 reduction was General Mills, cutting an estimated $2.52M.
  • FT Options fully exited Portola Pharmaceuticals, Inc. in Q3 2017, selling an estimated $2.31M.
  • FT Options's ten largest holdings make up 32% of its $66.4M portfolio in Q3 2017.
  • FT Options opened 108 new positions and closed 72 in Q3 2017.
  • FT Options's portfolio value rose 14% quarter-over-quarter to $66.4M.

Based on FT Options's 13F filing for Q3 2017, filed 13 Nov 2017.